Skip to main content

Study Of Sangamo’s Technology Published

The first clinical study of Sangamo Biosciences Inc.’s (Nasdaq: SGMO) zinc finger nuclease-based genome editing technology in humans was published in the New England Journal of Medicine. The stock price jumped $3.60 to $23.22.

Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.